Quantcast

Latest Acromegaly Stories

2011-06-06 05:00:00

NEW YORK and JERUSALEM, June 6, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, presented pharmacology results from clinical studies at the 12th International Pituitary Congress showing that Octreolin, a proprietary investigational new oral formulation of octreotide, demonstrated a consistent pharmacokinetic (PK) profile similar to that of subcutaneously injected octreotide acetate. Most important, the data illustrated that Octreolin reduced growth hormone (GH)...

2011-05-11 08:00:00

AMSTERDAM, May 11, 2011 /PRNewswire/ -- SynCo Bio Partners B.V., one of the leading GMP contract manufacturers of biopharmaceuticals, announced today that it has signed an agreement with Syntaxin to produce its novel drug candidate SXN101959. Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies for cell secretion control, is developing SXN101959 for the therapeutic treatment of Acromegaly as a primary indication. Under the agreement, SynCo will assist...

2011-02-05 00:00:41

Growth Hormones Direct offers natural replacement for synthetic Growth Hormones. Phoenix, AZ (Vocus/PRWEB) February 04, 2011 Growth Hormones Direct offers natural replacement for synthetic Growth Hormones. Natural homeopathic Human Growth Hormones formula provides comparable results without the potentially harmful side effects of synthetic Growth Hormones. The release of synthetic Growth Hormones for medical treatment purposes was a medical miracle in the lives of many. It was used as an...

2010-11-30 00:00:03

Growth Hormones Direct enumerates the Human Growth Hormone side effects of injection vs. homeopathic treatments. Phoenix, AZ (Vocus) November 28, 2010 Growth Hormones Direct enumerates the Human Growth Hormone side effects of injection vs. homeopathic treatments. Consumers should never access treatment without first considering the full range of potential Human Growth Hormone side effects and differentiating between the side effects attached to injections vs. homeopathic options. Human...

2010-09-22 00:27:00

EAST HANOVER, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Novartis Pharmaceuticals Corporation ("Novartis") (NYSE: NVS) announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal(1). Results will be presented at the 14th Congress of the European Neuroendocrine...

2010-08-26 08:00:00

ATLANTA, Aug. 26 /PRNewswire/ -- Much of Sultan Kosen's eight feet, two-inch stature rose up in an 17-year period starting at age 10, when the benign tumor in his brain's pituitary gland highjacked the organ, causing it to secrete massive amounts of growth hormone, making Mr. Kosen's body grow fast and grow without ceasing. He will need to wait several months to find out if his Gamma Knife® surgery last Thursday at the University of Virginia (UVA, Charlottesville, Va.)...

2010-06-27 23:01:00

NEW YORK and JERUSALEM, June 28 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration (FDA) has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer (TPE) technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone. If a New Drug Application...

2010-06-13 23:01:00

NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally. Octreolin demonstrated a PK profile similar to that of subcutaneously injected octreotide acetate. In addition, no serious adverse safety events were...

2010-02-11 10:36:00

WASHINGTON, Feb. 11 /PRNewswire-USNewswire/ -- Patient Access Network (PAN) Foundation will expand its services to provide co-payment assistance for medications to underinsured patients through five new funds -- including grants of up to $10,000 per year for prostate cancer patients. The other new funds will provide access to medications for patients with hepatitis B or C, non-kidney solid organ transplants, cytomegalovirus (or CMV), and acromegaly. These new funds are an expansion of...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.